The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice.

Autor: Martens UM; Clinic for Hematology, Oncology and Palliative Care, SLK Kliniken Heilbronn, Heilbronn, Germany.; MOLIT Institute for Personalized Medicine, Heilbronn, Germany., Schröder J; Practice for Hematology and Internal Oncology, Mülheim a.d.R, Germany., Bengsch F; iOMEDICO, Ellen-Gottlieb-Straße 19, 79106, Freiburg im Breisgau, Germany., Sellmann L; Practice for Oncology, Mönchengladbach, Germany., Busies S; iOMEDICO, Ellen-Gottlieb-Straße 19, 79106, Freiburg im Breisgau, Germany., Frank-Gleich S; Joint Practice for Internal Medicine, Hematology, Oncology, Gastroenterology, Halle (Saale), Germany., Zaiss M; Center for Interdisciplinary Oncology & Hematology, Freiburg, Germany., Decker T; Study Center for Oncology Ravensburg, Ravensburg, Germany., Schneeweiss A; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Research Center, Heidelberg, Germany., Schuler M; West German Cancer Center, Department of Medical Oncology, University Hospital Essen, University Duisburg-Essen, Essen, Germany., Grebhardt S; iOMEDICO, Ellen-Gottlieb-Straße 19, 79106, Freiburg im Breisgau, Germany., Zacharias S; iOMEDICO, Ellen-Gottlieb-Straße 19, 79106, Freiburg im Breisgau, Germany., Marschner N; iOMEDICO, Ellen-Gottlieb-Straße 19, 79106, Freiburg im Breisgau, Germany., Kasenda B; Medical Oncology, University Hospital and University of Basel, Basel, Switzerland., Potthoff K; iOMEDICO, Ellen-Gottlieb-Straße 19, 79106, Freiburg im Breisgau, Germany. manuscript@iomedico.com., Vannier C; iOMEDICO, Ellen-Gottlieb-Straße 19, 79106, Freiburg im Breisgau, Germany.

Publikováno v: BMC cancer [BMC Cancer] 2023 Jun 13; Vol. 23 (1), pp. 543. Date of Electronic Publication: 2023 Jun 13.

Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR.

Autor: Geßner C; POIS-Leipzig GbR Geßner u. Geßner, Leipzig, Germany., Fietz T; Outpatient Center for Hematology, Oncology and Gastroenterology, Singen, Germany., Losem C; Outpatient Center for Hematology and Oncology, Neuss, Germany., Lück A; Outpatient Center for Urology and Oncology, Rostock, Germany., Schulz H; Outpatient Center for Internal Oncology and Hematology, Frechen, Germany., Niemeier B; iOMEDICO, Freiburg im Breisgau, Germany., Groschek M; Outpatient Center for Hematology and Oncology, Stolberg, Germany., Eschenburg H; Outpatient Center for Internal Medicine, Hematology and Oncology, Güstrow, Germany., Weide R; Outpatient Center for Hematology and Oncology, Koblenz, Germany., Kretzschmar A; Outpatient Center for Internal Medicine, Hematology and Oncology, Leipzig, Germany., Frost N; Department of Infectious Diseases and Pulmonary Medicine, Charité-Universitätsmedizin, Berlin, Germany., Hipp J; Teva GmbH, Ulm, Germany., Harde J; iOMEDICO, Freiburg im Breisgau, Germany., Matillon CD; iOMEDICO, Freiburg im Breisgau, Germany., Grebhardt S; iOMEDICO, Freiburg im Breisgau, Germany., Potthoff K; iOMEDICO, Freiburg im Breisgau, Germany.

Publikováno v: Current medical research and opinion [Curr Med Res Opin] 2022 Dec; Vol. 38 (12), pp. 2191-2199. Date of Electronic Publication: 2022 Sep 01.

70P Genetic alterations and immune cell infiltration with potential impact on PD-(L)1 targeted treatment in various cancer entities: Biobank research project of the INFINITY registry

Autor: Vannier, C., Jermann, P., Matter, M., Läubli, H., Grebhardt, S., Wright, P., Kasenda, B., Marschner, N.W.

Publikováno v: In Annals of Oncology October 2022 33 Supplement 8:S1404-S1405

Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.

Autor: Dechow T; Onkologie Ravensburg, Ravensburg, Germany., Aldaoud A; Gemeinschaftspraxis für Hämatologie & Onkologie, Leipzig, Germany., Behlendorf T; Gemeinschaftspraxis für Innere Medizin, Hämatologie & Onkologie, Halle (Saale), Germany., Knauf W; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt am Main, Germany., Eschenburg H; Internistische Gemeinschaftspraxis, Güstrow, Germany., Groschek M; Praxis für Hämatologie und Onkologie, Stolberg, Germany., Hansen R; Schwerpunktpraxis für Hämatologie und Onkologie, Kaiserlautern, Germany., Söling U; Hämato-onkologisches Zentrum Kassel GmbH, Kassel, Germany., Grebhardt S; iOMEDICO, Freiburg im Breisgau, Germany., Siebenbach HU; iOMEDICO, Freiburg im Breisgau, Germany., Vannier C; iOMEDICO, Freiburg im Breisgau, Germany., Potthoff K; iOMEDICO, Freiburg im Breisgau, Germany.

Publikováno v: European journal of haematology [Eur J Haematol] 2022 Feb; Vol. 108 (2), pp. 133-144. Date of Electronic Publication: 2021 Nov 15.

1884P Patient, nurse and physician preferences: Final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or On-body injector (OBI) in cancer patients

Autor: Metz, M., Semsek, D., Rogmans, G., Hutzschenreuter, U., Fietz, T., Harde, J., Zacharias, S., Hielscher, C., Lorenz, A., Zahn, M-O., Guth, D., Grebhardt, S., Fichter, C.D., Potthoff, K.

Publikováno v: In Annals of Oncology September 2020 31 Supplement 4:S1071-S1071